161 related articles for article (PubMed ID: 26577959)
1. Pathogen Reduction Technology in Transfusion: Where Do We Stand?
Khurshid M; Moiz B
J Coll Physicians Surg Pak; 2015 Nov; 25(11):779-80. PubMed ID: 26577959
[No Abstract] [Full Text] [Related]
2. Inactivation of pathogens in blood and blood products.
Ben-Hur E
Med Health R I; 1998 Dec; 81(12):396-9. PubMed ID: 9884539
[No Abstract] [Full Text] [Related]
3. Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands.
Salunkhe V; van der Meer PF; de Korte D; Seghatchian J; Gutiérrez L
Transfus Apher Sci; 2015 Feb; 52(1):19-34. PubMed ID: 25620756
[TBL] [Abstract][Full Text] [Related]
4. [Immunobiology--the neglected side of transfusion].
Flesland O; Solheim BG
Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2493. PubMed ID: 11070981
[No Abstract] [Full Text] [Related]
5. [Pathogen reduction of blood components: from financial issues to possible long-term consequences].
Canellini G; Wasserfallen JB; Tissot JD
Transfus Clin Biol; 2011 Aug; 18(4):493-7. PubMed ID: 21719339
[TBL] [Abstract][Full Text] [Related]
6. [Pathogen inactivation processes applicable to cellular products: the Canadian perspective].
Delage G
Transfus Clin Biol; 2011 Aug; 18(4):485-7. PubMed ID: 21715210
[TBL] [Abstract][Full Text] [Related]
7. Pathogen inactivation in cellular blood components: clinical trials and implications of introduction to transfusion medicine.
AuBuchon JP
Vox Sang; 2002 Aug; 83 Suppl 1():271-5. PubMed ID: 12617151
[No Abstract] [Full Text] [Related]
8. [Pathogen reduction: a clinician view].
Socié G
Transfus Clin Biol; 2011 Aug; 18(4):491-2. PubMed ID: 21715208
[No Abstract] [Full Text] [Related]
9. [Transfusion of blood and products derived from blood].
Wautier JL
Rev Prat; 1999 Feb; 49(4):409-13. PubMed ID: 10319693
[No Abstract] [Full Text] [Related]
10. [The risk of substitution therapy with blood and blood products].
Baumgarten R
Z Arztl Fortbild (Jena); 1994 Jan; 88(1):3-4. PubMed ID: 8154136
[No Abstract] [Full Text] [Related]
11. [Expected limits (and possible consequences) of pathogen inactivation technology].
Lefrère JJ
Transfus Clin Biol; 2011 Aug; 18(4):468-71. PubMed ID: 21802331
[TBL] [Abstract][Full Text] [Related]
12. [Pathogen inactivation technologies: a complex but necessary debate].
Andreu G; Cazenave JP; Garraud O; Lefrère JJ
Transfus Clin Biol; 2011 Aug; 18(4):443. PubMed ID: 21783399
[No Abstract] [Full Text] [Related]
13. [Bacterial detection leading to pathogen inactivation].
Morel P; Deschaseaux M; Naegelen C; Bardiaux L; des Floris MF; Pouthier F
Transfus Clin Biol; 2005 Jun; 12(2):142-9. PubMed ID: 15894506
[TBL] [Abstract][Full Text] [Related]
14. Residual risks of blood transfusion in Rhode Island.
Sweeney JD; Kurtis J; Starakiewicz J
Med Health R I; 2005 Jul; 88(7):224-5, 228-31. PubMed ID: 16184827
[No Abstract] [Full Text] [Related]
15. Improving blood safety and patient outcomes with pathogen reduction technology.
Goodrich RP; Ettinger A; Radziwon PM; Rock G
Transfus Apher Sci; 2011 Dec; 45(3):229-38. PubMed ID: 22078570
[No Abstract] [Full Text] [Related]
16. Microbe police. Who's watching disinfection and sterilization?
Cokendolpher JC; Haukos JF
Mater Manag Health Care; 1997 Jan; 6(1):20, 22. PubMed ID: 10164639
[No Abstract] [Full Text] [Related]
17. Pathogen reduction: state of reflection in Ireland.
Murphy WG
Transfus Clin Biol; 2011 Aug; 18(4):488-90. PubMed ID: 21803629
[TBL] [Abstract][Full Text] [Related]
18. Clinical trials for pathogen reduction in transfusion medicine: a review.
McClaskey J; Xu M; Snyder EL; Tormey CA
Transfus Apher Sci; 2009 Dec; 41(3):217-25. PubMed ID: 19793679
[TBL] [Abstract][Full Text] [Related]
19. Evolution of microbial safety.
Barbara JA
Hematol J; 2004; 5 Suppl 3():S69-73. PubMed ID: 15190282
[No Abstract] [Full Text] [Related]
20. Commentary on the current opinions on blood components safety/efficacy.
Seghatchian J
Transfus Apher Sci; 2006 Jun; 34(3):241-2. PubMed ID: 16807111
[No Abstract] [Full Text] [Related]
[Next] [New Search]
